A Look into Prostate Cancer Therapeutics Industry……Deep Analysis…..


The global prostate cancer therapeutics market is expected to reach USD 12.0 billion by 2025, according to a new report by Grand View Research, Inc. According to the American Cancer Society, approximately 1 in 7 men will be diagnosed with prostate cancer in their lifetime. As per Cancer Research, a government institute, in the UK, 46,690 new cases of prostate cancer were diagnosed out of which 11,287 patients died in 2014.
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
Supportive initiatives undertaken by key players in collaboration with various governments to create more awareness of clinical symptoms about prostate cancer and availability of screening & diagnostic tests such as Prostate-Specific Antigen (PSA) and Digital Rectal Exam (DRE) resulting in early detection. Early detection helps in quick and on time treatment and assists in deciding treatment regimens. In addition, major players including Astella, Inc., Sanofi, Dendreon Corporation, AstraZeneca, and Johnson & Johnson are focusing on development of effective and safe therapeutic products to treat tumor. Moreover, these players have various established brands such as Zytiga, Xtandi, Eligard, Taxotere, Provenge, and Xofigo, which hold a strong position in the market. In addition, there are many drugs in pipeline such as Tc-99m (Progenics), radium-223 dichloride (Xofigo, Bayer), and ODM-201 (Orion and Bayer), which are in their phase 3 studies and are expected to enter the market during the forecast period. In addition, patents of many existing products are expiring during the forecast period. As a result, generic products are anticipated to penetrate the market. All these factors together are expected to propel growth.
In Canada, Prostate Cancer Foundation of Canada supports research, cure, and prevention of prostate cancer through an online portal. This portal provides detailed information regarding symptoms, diagnosis, and commercially available treatment options. Such portals offer free access to people all around the world, which is resulting in growth.
To Request Sample Copy of this report, click the link:
https://www.grandviewresearch.com/industry-analysis/prostate-cancer-therapeutics-market/request/rs1
Further key findings from the study suggest:
·         The growing incidence of prostate cancer across the globe is expected to drive growth
·         The market is segmented into hormonal therapy including Luteinizing Hormone Releasing Hormone (LHRH) agonist, LHRH antagonist & antiandrogen; chemotherapy; immunotherapy, and targeted therapy
·         Zytiga (Johnson & Johnson) is considered as a gold standard product for the treatment of prostate cancer and holds a strong position. However, Xtandi (Astella, Inc.) and Zytiga are competing with each other. The degree of competition is projected to elevate during the forecast period. Thus, hormonal therapy holds the largest share.
·         Provenge (Dendreon Corporation) is the only immunotherapy drug mainly used in the treatment of advanced or metastasis of such cancerous cells
·         In addition, there are many promising immunotherapy drugs in the pipeline such as INO-5150 SynCon and PROSTVAC (Bavarian Nordic), which are expected to enter the market in the near future. Thus, this drug class is projected to be the fastest growing segment.
·         North America dominated the global market. Rising prevalence and mortality rate associated with such tumors in the U.S. is the primary reason for the dominance of the region.
·         Asia Pacific is anticipated to be the fastest growing region over the forecast period. Rising awareness regarding prostate cancer in Asian countries including China, Japan, & India, would be the major factor driving the growth.
·         Some of the major players include, but are not limited to, Johnson & Johnson; Astella, Inc.; Sanofi; Ipsen; Bayer AG; AstraZeneca; Valeant Pharmaceuticals North America LLC (Dendreon Corporation). These major players dominate the market owing to their strong brand identity and extensive geographic reach.
The global prostate cancer therapeutics market size was valued at USD 7.9 billion in 2016 and is expected to grow at a CAGR of 4.8% over the forecast period. As per data published by the World Cancer Research Fund International, more than 1.1 million cases of prostate cancer were reported in 2012, which accounts for around 8 percent of the total tumor cases. Although the exact cause of prostate cancer is not known, factors associated with it include overweight, obesity, and history of any other tumorous growth. Even patients with cardiovascular diseases are prone to metastasis of cancer. Thus, rising incidence rate of the above-mentioned conditions is driving market growth.
Adoption of innovative technologies in screening & diagnostic tests is projected to drive growth. The incorporation of multiparametric MRI (mp-MRI) can significantly improve the detection of tumor and also provide confirmation whether there is a need for tissue biopsy. In addition, market players are investing in research for the development of therapeutic products for the treatment of such tumors. For instance, there is a strong pipeline of products such as Tc-99m (Progenics), radium-223 dichloride (Xofigo, Bayer), ODM-201 (Orion and Bayer), which are in their phase 3 studies and are projected to enter the market in the near future. In addition, many generic products are likely to enter the market owing to the expiry of patents of the major existing products during the forecast period. Thus, these factors are expected to drive growth.
Have any Query? Ask our Experts:
https://www.grandviewresearch.com/inquiry/1120/ibb
Along with screening & diagnostic tests, awareness about availability of medicines amongst public is also of prime importance to break the social stigma associated with tumor treatment and encourage patients to avail treatment in time. The governments of developed countries are taking efforts to conduct & implement programs for creating awareness of screening tests, such as Prostate-Specific Antigen (PSA) blood tests and Digital Rectal Exam (DRE) for male patients above 50 years. Prostate Cancer Canada has been established to support research, cure, and prevention of prostate cancer. Such awareness programs are also being undertaken in developing countries like China, India, & Brazil.
However, high cost associated with tissue biopsy, especially during advanced stage of tumor and consultation fees of the physician is expected to slow down growth. In addition, factors such as poor reimbursement of treatment cost may affect the adoption rate of treatment procedures negatively.
Grand View Research has segmented the prostate cancer therapeutics market by drug:
Drugs Outlook (Revenue, USD billion; 2014 - 2025)
·         Hormonal Therapy
o    Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists
o  Zytiga
o  Gonax
o    Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
o  Lupron
o  Zoladex
o  Eligard
o  Decapeptyl
o  Vantas
o  Others
o    Anti-Androgen
o  Xtandi
o  Casodex
o    Chemotherapy
o  Taxotere
o  Jevtana
o    Immunotherapy
o  Provenge
o    Targeted Therapy
o  Xofigo
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


Comments

Post a Comment

Popular posts from this blog

Foot Orthotic Insoles Market 2026: What Will Be Changes In Investment Ratio With Opportunity Analysis?? |Grand View Research, Inc.

Image
The global foot orthotic insoles market size is expected to reach USD 5.5 billion by 2026 , according to a new report by Grand View Research, Inc., exhibiting a 6.3% CAGR during the forecast period. Growing incidence of diabetes and plantar fasciitis are expected to drive the market over the forecast period. Moreover, rapid urbanization and increasing disposable income are anticipated to propel growth in future. Technological advancements, spurred by ongoing investments in R&D, are expected to increase growth potential in the coming years. Moreover, rise in geriatric population, which is susceptible to orthopedic disorders, is impelling product demand globally. For instance, in 2017 as per the U.S. Census Bureau, the number of people aged 65 or older increased by 1.6 million from 2014 to 2015. In addition, increasing incidence of sports injuries and rising prevalence of osteosarcoma in the region has led to the need for various orthotics devices, which is expected to drive ...
Read more

A Look into Smokehouse Industry……Deep Analysis…..

Image
The global smokehouse market size is anticipated to reach USD 157.2 million by 2025 , according to a new report by Grand View Research, Inc. The market is anticipated to register a CAGR of 2.2% during the forecast period. Rising need for a healthy lifestyle has led consumers to prefer griller or barbequed food over fried food and other kinds of fast food. This trend is expected to have a positive impact on the market growth. The home care & decor industry has been witnessing inconsistent growth, since the Covid 19 outbreak. As a result of the ongoing pandemic crisis, there has been a drop in the overall performance of discretionary products such as decorative fixtures, bedding products, to name a few. The virus outbreak has, however, led to substantial growth in categories such as cleaning and hygiene products. Prominent growth in the e-commerce business is also one of the positive influences of the outbreak, wherein companies are focusing on expanding their distribution ...
Read more

A Look into Shapewear Industry……Deep Analysis…..

Image
The global shapewear market size is expected to reach USD 3.80 billion by 2025 registering a CAGR of 7.7%, according to a new report by Grand View Research, Inc. The introduction of various products according to the type of garments is expected to support the market growth in the years to come. Growing target population across the globe is also augmenting the market growth. Changing lifestyle incurs increased investment in fitness and related accessories, which has positively impacted the market growth. The clothing, footwear, & accessories industry is anticipated to witness checkered growth throughout 2020, as a result of the unprecedented supply chain disruptions caused by the COVID-19 outbreak worldwide. The expected decline in the global sales of clothing, footwear, & accessories is attributable to massive supply chain disruptions across significant export markets, including China and India. However, the industry is likely to recover over the forecast timeframe,...
Read more